TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has announced the appointment of Anna Moore, PhD, as Chair of its Scientific Advisory Board, alongside the execution of a sponsored research agreement with Michigan State University. The moves are aimed at advancing the company's RNA-based therapeutic pipeline, particularly its lead candidate, TTX-MC138, which targets metastatic tumors.
The sponsored research agreement with Michigan State University is expected to support the development of TTX-MC138, including evaluation in combination with other therapies. Dr. Moore will provide strategic guidance on research and development efforts focused on treating advanced cancers. TransCode Therapeutics is a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer.
TTX-MC138 is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
The full press release can be viewed at https://ibn.fm/NA2NH. For the latest news and updates relating to RNAZ, visit the company’s newsroom at https://ibn.fm/RNAZ.
